Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management.

Cell Mol Biol Lett · 2025 · PMC12172322 · PMID 40524185

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In a phase II clinical trial, the endpoint did not reach statistical significance: obexelimab-treated patients (42.0%) versus placebo-treated patients (28.6%).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.